173 related articles for article (PubMed ID: 3286879)
1. Ifosfamide.
Zalupski M; Baker LH
J Natl Cancer Inst; 1988 Jun; 80(8):556-66. PubMed ID: 3286879
[TBL] [Abstract][Full Text] [Related]
2. Ifosfamide--pharmacology, safety and therapeutic potential.
Brade WP; Herdrich K; Varini M
Cancer Treat Rev; 1985 Mar; 12(1):1-47. PubMed ID: 3896483
[No Abstract] [Full Text] [Related]
3. Ifosfamide vs cyclophosphamide in cancer therapy.
Weiss RB
Oncology (Williston Park); 1991 May; 5(5):67-76; discussion 76-82, 84-6. PubMed ID: 1653004
[TBL] [Abstract][Full Text] [Related]
4. Ifosfamide: new idications-new dose strength. Limited evidence of effectiveness.
Prescrire Int; 1998 Apr; 7(34):45-7. PubMed ID: 10183382
[TBL] [Abstract][Full Text] [Related]
5. Ifosfamide: European perspective.
Burkert H
Semin Oncol; 1982 Dec; 9(4 Suppl 1):28-35. PubMed ID: 6761866
[No Abstract] [Full Text] [Related]
6. The anticancer spectrum of ifosfamide.
Hunter HL; Harrison EF
Semin Oncol; 1982 Dec; 9(4 Suppl 1):96-100. PubMed ID: 6761868
[No Abstract] [Full Text] [Related]
7. Ifosfamide and Mesna in advanced malignancies.
Li GC; Brock N; Li JQ; Guan ZZ; He YJ
Chin Med J (Engl); 1988 Mar; 101(3):213-20. PubMed ID: 3136996
[No Abstract] [Full Text] [Related]
8. Evaluation of a cooperative clinical study of the cytostatic agent ifosfamide.
Schnitker J; Brock N; Burkert H; Fichtner E
Arzneimittelforschung; 1976; 26(10):1783-92. PubMed ID: 798586
[TBL] [Abstract][Full Text] [Related]
9. Ifosfamide in the treatment of malignant epithelial ovarian tumors.
Lissoni AA; Fei F; Rossi R; Fruscio R; Villa A; Zani G
Oncology; 2003; 65 Suppl 2():59-62. PubMed ID: 14586150
[TBL] [Abstract][Full Text] [Related]
10. [Clinical experience with the cytostatic drug ifosfamide].
Ritter S; Schröder HJ
Med Welt; 1977 Sep; 28(35):1395-1400. PubMed ID: 70737
[No Abstract] [Full Text] [Related]
11. Ifosfamide-based drug combinations: preclinical evaluation of drug interactions and translation into the clinic.
Vanhoefer U; Schleucher N; Klaassen U; Seeber S; Harstrick A
Semin Oncol; 2000 Feb; 27(1 Suppl 1):8-13. PubMed ID: 10697038
[TBL] [Abstract][Full Text] [Related]
12. Ifosfamide in the treatment of soft tissue sarcomas.
Connelly EF; Budd GT
Semin Oncol; 1996 Jun; 23(3 Suppl 6):16-21. PubMed ID: 8677442
[TBL] [Abstract][Full Text] [Related]
13. [Treatment of bronchogenic cancer and lung metastases of solid tumors with ifosfamid (author's transl)].
Hoefer H; Scheef W; Titscher R; Kokron O
Osterr Z Onkol; 1974; (1):3-7. PubMed ID: 4619650
[No Abstract] [Full Text] [Related]
14. Ifosfamide/mesna. A review of its antineoplastic activity, pharmacokinetic properties and therapeutic efficacy in cancer.
Dechant KL; Brogden RN; Pilkington T; Faulds D
Drugs; 1991 Sep; 42(3):428-67. PubMed ID: 1720382
[TBL] [Abstract][Full Text] [Related]
15. Phase I study of high-dose ifosfamide, carboplatin and etoposide with autologous hematopoietic stem cell support.
Elias AD; Ayash LJ; Wheeler C; Schwartz G; Tepler I; Gonin R; McCauley M; Mazanet R; Schnipper L; Frei E
Bone Marrow Transplant; 1995 Mar; 15(3):373-9. PubMed ID: 7599561
[TBL] [Abstract][Full Text] [Related]
16. Cyclophosphamide versus ifosfamide for paediatric and young adult bone and soft tissue sarcoma patients.
Mulder RL; Paulides M; Langer T; Kremer LC; van Dalen EC
Cochrane Database Syst Rev; 2012 Dec; 12():CD006300. PubMed ID: 23235629
[TBL] [Abstract][Full Text] [Related]
17. Cyclophosphamide versus ifosfamide: a randomized phase II trial in adult soft-tissue sarcomas. The European Organization for Research and Treatment of Cancer [EORTC], Soft Tissue and Bone Sarcoma Group.
Bramwell VH; Mouridsen HT; Santoro A; Blackledge G; Somers R; Verweij J; Dombernowsky P; Onsrud M; Thomas D; Sylvester R
Cancer Chemother Pharmacol; 1993; 31 Suppl 2():S180-4. PubMed ID: 8453694
[TBL] [Abstract][Full Text] [Related]
18. [Ifosfamide in pediatric malignancy--experiences in the Northern Israel Oncology Center].
Roguin A; Ben Arush MW; Higasi A; Kuten A
Harefuah; 1996 Apr; 130(8):511-4, 584. PubMed ID: 8765870
[TBL] [Abstract][Full Text] [Related]
19. Cyclophosphamide versus ifosfamide for paediatric and young adult bone and soft tissue sarcoma patients.
Mulder RL; Paulides M; Langer T; Kremer LC; van Dalen EC
Cochrane Database Syst Rev; 2010 Feb; (2):CD006300. PubMed ID: 20166081
[TBL] [Abstract][Full Text] [Related]
20. Treatment of refractory malignant neoplasms with ifosfamide as single agent and in combination chemotherapy.
Retsas S
Cancer Treat Rev; 1983 Sep; 10 Suppl A():151-7. PubMed ID: 6627241
[No Abstract] [Full Text] [Related]
[Next] [New Search]
